A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
A metatarsophalangeal joint sprain is an injury to the connective tissue between the foot and a toe (at a metatarsophalangeal joint, one of the joints in the ball of the foot). When the big toe is involved, it is known as "turf toe".
=== Fetal development impacts === Multiple epidemiological studies of people living in Europe, the United States, and China have linked in utero exposure to PAHs, through air pollution or parental occupational exposure, with poor fetal growth, reduced immune function, and poorer neurological development, including lower IQ.
Dispase is a protease which cleaves fibronectin, collagen IV, and to a lesser extent collagen I. It is found in some bacteria and can be isolated from culture filtrates of Bacillus polymyxa. It can be extracted, purified, and used in research. It can be particularly useful to separate embryonic epithelia and mesenchyme. Dispase II is specific for the cleavage of leucine-phenylalanine bonds. Dispase is often used to digest adhering primary cells in culture, since this treatment turned out to be milder than trypsin digestion (Sinclair et al., 2013). A recent article also finds that dispase can digest serine-phenylalanine. Dispase intravitreal injection can be used in the modeling of proliferative vitreoretinopathy in different animals.
Sources: en.wikipedia.org
=== Liquid biomolecular condensates === Liquid–liquid phase separation (LLPS) generates a subtype of colloid known as an emulsion that can coalesce to form large droplets within a liquid. Ordering of molecules during liquid–liquid phase separation can generate liquid crystals rather than emulsions. In cells, LLPS produces a liquid subclass of biomolecular condensate that can behave as either an emulsion or liquid crystal. The term biomolecular condensates was introduced in the context of intracellular assemblies as a convenient but non-exclusionary term to describe non-stoichiometric assemblies of biomolecules. The choice of language here is specific and important. It has been proposed that many biomolecular condensates form through liquid–liquid phase separation (LLPS) to form colloidal emulsions or liquid crystals in living organisms, as opposed to liquid–solid phase separation to form crystals/aggregates in gels, sols or suspensions within cells or extracellular secretions. However, unequivocally demonstrating that a cellular body forms through liquid–liquid phase separation is challenging, because different material states (liquid vs. gel vs. solid) are not always easy to distinguish in living cells. The term "biomolecular condensate" directly addresses this challenge by making no assumption regarding either the physical mechanism through which assembly is achieved, nor the material state of the resulting assembly.
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 4 September The Tin Snail, about the Citroën 2CV; the 2CV was first introduced in October 1948; André Citroën saw himself as a French Henry Ford, and met American automotive industrialists in October 1931, including Henry Ford at the newly opened Ford Engineering Laboratory; the industrial historian Patrick Fridenson; Citroën lit up the Eiffel Tower in Citroën regalia, for publicity; but although André Citroën followed and admired Henry Ford, Citroën were innovative themselves, on 18 April 1934 the company launched the world's first mass-produced front-wheel drive car, the Citroën Traction Avant, when the company was narrowly avoiding bankruptcy; André Citroën died in 1935 and his company, being heavily in debt, was taken over by Édouard Michelin (brother of André Michelin); Fiat introduced its similar Fiat 500 in 1935, designed by Dante Giacosa; Ferdinand Porsche designed a new mass-produced car with rear air-cooled horizontally-opposed four-cylinder engine; France did not have such a car to Germany, so Citroën developed the Toute Petite Voiture (TPV), a proposal of Pierre Michelin - he brought in André Lefèbvre, who had designed the front-wheel-drive system of the Traction Avant and was a former aircraft engineer of Voisin, and led by Pierre-Jules Boulanger; Lefèbvre came from the aviation industry, and to save weight, made the car out of aluminium; the car had a torsion bar suspension, with eight torsion bars; Flaminio Bertoni, an Italian, was head of exterior design at Citroën, from 1932 to 1964; Carl Olsen, head of Citroën exterior design from 1982 to 1987; Alex Moulton, the Cambridge-educated mechanical engineer, who designed the suspension for the innovative Mini, in the late 1950s; Lucien Gerard, from Talbot, and Walter Becchia, who designed the two-cylinder water-cooled horizontally opposed engine. Narrated by Peter Jones, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 11 September Deep Trouble, about the North Sea oil industry; the beginning of 1986 saw peak production of North Sea oil; finding new oil reserves would be from deeper oil fields, that cost more money to extract; at the same time the oil price plummeted, with over 15,000 job losses in the British oil industry by the end of 1986; Vickers Ltd entered the oil exploration industry; submersible craft were helping exploration of oil, with remotely operated craft becoming important. Narrated by Martin Jarvis, produced by Patrick Uden, directed by Paul Fabricius, made by Uden Associates 18 September What They Don't Tell You When They Sell You a Computer, about professionalism in the computer hardware industry; Eddy Shah from the Today newspaper, and their new unreliable computer system; Brian Wilson of First Computer believed that the computer hardware retailing industry were largely unprofessional unscrupulous cowboys; the National Computing Centre (NCC) was set up by the government in 1966, to provide advice; BP opened its own Microshop, to circumvent the cowboys, and assist with technical jargon, and connecting devices; due to warp-drive technical obsolescence in the 1980s, yesterday's computers rapidly lost all total value; Iain Callaghan, operations director of John Menzies newspaper distribution business, and how computer databases could process newsagents' daily orders much quicker and reliably; Geoff Dalby, head of data at Woolwich Equitable Building Society, which had called off a merger with the Nationwide Building Society, as their computer systems would not work together; greater computer automation of the personal finance industry could lead to much less day-to-day contact with individual customers; David Bailey of Phillips & Drew. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 25 September Precisely in Profit, about manufacturing to exact margins. Produced by Glyn Jones, directed by Eben Wilson, made by Quanta 2 October Now Eat This, about snack foods. Produced by Edward Poulter, directed by Mike Tomlinson, made by London Scientific Films 9 October Growing up with Rockets, a personal, and underreported, view of early elementary rocketry from 1950, starting with captured German V-2 rockets; the former 1970 class of Cocoa Beach High School; failed launches would land in the Banana River; NASA was formed in July 1958, in a coherent response to the Russian launches in 1957; the President visits Cocoa Beach to celebrate the US getting a man to orbit the Earth in February 1962; the nearby Patrick Air Force Base; Syncom 3 was launched on 19 August 1964, the world's first geostationary communication satellite, on a Delta rocket; the minutes leading up to the first launch of STS-1 in April 1981. Directed and a first hand account of Nancy Yasecko, produced by Patrick Uden, made by Uden Associates 16 October Shock Trauma, about the Baltimore Shock Trauma Center (R Adams Cowley Shock Trauma Center). A Canadian production, produced by Patrick Uden, made by National Film Board of Canada and Uden Associates 23 October Drink Drive and Murder; it featured two court cases in the US, where a 33 year old killed a couple in their 20s, and a 17 year old who killed a couple of teenagers, and a Californian drink-drive reform centre; in some US states, if you kill when drunk, the charge is murder. A Canadian production, made by Uden Associates and the National Film Board of Canada 30 October The New Magicians, about film special effects; Gertie the Dinosaur in 1914 and The Sinking of the Lusitania in 1918; the King Kong (1933 film); the 1950s and 1960s saw modest increases in special effects, notably Forbidden Planet in 1956, until 2001: A Space Odyssey was important in 1968; another important film was Star Wars (film) in 1977, along with Close Encounters of the Third Kind, Tron in 1982 and The Last Starfighter in 1984. A Canadian production, produced by Ken McKay, made by TV Ontario 6 November Pioneers of the Future, about the development of microchips, such as Steve Dorsey, who invented the word processor. A Canadian production, produced by Ken McKay, made by Uden Associates and TV Ontario 13 November Skyscraper, about Old Madison Square Gardens and skyscrapers in Chicago and New York; Arthur Nusbaum; architect Stanley Tigerman; the tallest masonry-only building was 16 storeys high; the Great Chicago Fire in October 1871, which allowed different, and stronger, structures of building to be built instead; the 1902 Flatiron Building; architect Jack Hartray; mechanical engineer George Strakosch; the 1908 600-feet Singer Building; the 1912 800-feet Woolworth Building; the 1915 Equitable Building (Manhattan); the 1930 900-feet Chrysler Building; the 1931 1250-feet Empire State Building; mechanical engineer David Stillman; structural engineer Charles Thornton; architect Robert Sobel; structural engineer Leslie E. Robertson; civil engineer Alan Garnett Davenport of the University of Western Ontario; architect Bruce Graham; architect Harry Weese; architect Moshe Safdie. Narrated by William Woollard, produced by Nicola Glucksmann, directed by Karl Sabbagh, made by InCA
He also holds patents for several processes he has developed. Ajayaghosh is associated with several science journals around the world. He is an associate editor of Physical Chemistry Chemical Physics (PCCP), published by the Royal Society of Chemistry and a senior editor of the Bulletin of the Chemical Society of Japan. He is a former member of the advisory board of RSC Advances and sits in the editorial board of Chemistry: An Asian Journal. He has also guided several master's and doctoral scholars in their studies and has been involved in programs for the popularization of science and science awareness campaigns.
Clomipramine is an extremely strong SRI by all accounts. Its affinity for the SERT was reported in one study using human tissues to be 0.14 nM, which is considerably higher than that of other TCAs. For example, the TCAs with the next highest affinities for the SERT in the study were imipramine, amitriptyline, and dosulepin (dothiepin), with Ki values of 1.4 nM, 4.3 nM, and 8.3 nM, respectively. In addition, clomipramine has a terminal half-life that is around twice as long as that of amitriptyline and imipramine. In spite of these differences however, clomipramine is used clinically at the same usual dosages as other serotonergic TCAs (100–200 mg/day). Some health authorities recommend daily dosage is in the range of 30 to 75 mg in single or divided doses. Initial dosage should be 10 mg/day with gradual increments to 30–150 mg/day in divided doses or as a single dose at bedtime. Health Canada recommends maximum dose for outpatients is preferred at 200 mg/day. Sustained-release 75 mg formulation may be preferable at doses above 150 mg/day (i.e. 200 mg to 250 mg/day). It achieves typical circulating concentrations that are similar in range to those of other TCAs but with an upper limit that is around twice that of amitriptyline and imipramine. For these reasons, clomipramine is the most potent SRI among the TCAs and is far stronger as an SRI than other TCAs at typical clinical dosages. In addition, clomipramine is more potent as an SRI than any selective serotonin reuptake inhibitors (SSRIs); it is more potent than paroxetine, which is the strongest SSRI.
Sources: en.wikipedia.org
=== Bacterial virulence === Neutrophils and other phagocytes use peroxide to kill bacteria. The enzyme NADPH oxidase generates superoxide within the phagosome, which is converted via hydrogen peroxide to other oxidising substances like hypochlorous acid which kill phagocytosed pathogens. In individuals with chronic granulomatous disease (CGD), phagocytic peroxide production is impaired due to a defective NADPH oxidase system. Normal cellular metabolism will still produce a small amount of peroxide and this peroxide can be used to produce hypochlorous acid to eradicate the bacterial infection. However, if individuals with CGD are infected with catalase-positive bacteria, the bacterial catalase can destroy the excess peroxide before it can be used to produce other oxidising substances. In these individuals the pathogen survives and becomes a chronic infection. This chronic infection is typically surrounded by macrophages in an attempt to isolate the infection. This wall of macrophages surrounding a pathogen is called a granuloma. Many bacteria are catalase positive, but some are better catalase-producers than others. Some catalase-positive bacteria and fungi include: Nocardia, Pseudomonas, Listeria, Aspergillus, Candida, E. coli, Staphylococcus, Serratia, B. cepacia and H. pylori.
=== Bellagio Center === The foundation also owns and operates the Bellagio Center in Bellagio, Italy. The center has several buildings, spread across a 50-acre (200,000 m2) property, on the peninsula between lakes Como and Lecco in Northern Italy. The center is sometimes referred to as the "Villa Serbelloni", the property bequeathed to the foundation in 1959 under the presidency of Dean Rusk (who was later to become U.S. President Kennedy's secretary of state).
Morpholino Also phosphorodiamidate Morpholino oligomer. A synthetic nucleic acid analogue connecting a short sequence of nucleobases into an artificial antisense oligomer, used in genetic engineering to knockdown gene expression by pairing with complementary sequences in naturally occurring RNA or DNA molecules, especially mRNA transcripts, thereby inhibiting interactions with other biomolecules such as proteins and ribosomes. Morpholino oligomers are not themselves translated, and neither they nor their hybrid duplexes with RNA are attacked by nucleases; also, unlike the negatively charged phosphates of normal nucleic acids, the synthetic backbones of Morpholinos are electrically neutral, making them less likely to interact non-selectively with a host cell's charged proteins. These properties make them useful and reliable tools for artificially generating mutant phenotypes in living cells.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.